Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506969 · ClinicalTrials.gov registry record · Phase 2
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
A Phase 2 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT05506969 is a Phase 2 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 200 participants.
The verdict
NCT05506969, a Phase 2 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
Interventions
- BIOLOGICAL rF1V-1018
- BIOLOGICAL rF1V vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05506969
The ClinicalTrials.gov registry entry for NCT05506969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rF1V-1018 is the first listed.
NCT05506969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05506969 about?
NCT05506969 is a clinical study titled "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age". Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
What is the current status of trial NCT05506969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-08-09. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT05506969?
The interventions under investigation include: rF1V-1018 (BIOLOGICAL), rF1V vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05506969?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.